Bruker Gestion
Gestion contrôle des critères 4/4
Le PDG Bruker est Frank Laukien, nommé en Feb1991, a un mandat de 33.75 ans. La rémunération annuelle totale est $ 5.86M, composée du salaire de 15.8% et des bonus 84.2%, y compris les actions et options de la société. détient directement 26.62% des actions de la société, d'une valeur de $ 2.30B. La durée moyenne de mandat de l'équipe de direction et du conseil d'administration est respectivement 10.6 ans et 9.3 ans.
Informations clés
Frank Laukien
Directeur général
US$5.9m
Rémunération totale
| Pourcentage du salaire du PDG | 15.8% |
| Durée du mandat du directeur général | 33.8yrs |
| Propriété du PDG | 26.6% |
| Durée moyenne d'occupation des postes de direction | 10.6yrs |
| Durée moyenne du mandat des membres du conseil d'administration | 9.3yrs |
Mises à jour récentes de la gestion
Recent updates
Bruker's (NASDAQ:BRKR) Anemic Earnings Might Be Worse Than You Think
Nov 14
Bruker: Still Challenged, Certainly Margins
Nov 02Earnings Tell The Story For Bruker Corporation (NASDAQ:BRKR)
Oct 25We Think Bruker (NASDAQ:BRKR) Is Taking Some Risk With Its Debt
Sep 10Bruker: Multiple Risks And Declining Returns On Capital Aren't Priced In
Aug 22Is It Too Late To Consider Buying Bruker Corporation (NASDAQ:BRKR)?
Jul 22Bruker Corporation's (NASDAQ:BRKR) Business Is Yet to Catch Up With Its Share Price
Jun 09Bruker: A Confusing Acquisition Spree
May 31Bruker's (NASDAQ:BRKR) Promising Earnings May Rest On Soft Foundations
May 09Bruker Corporation: An Aggressive Acquisition Strategy
Apr 24Bruker Offers Upside With Key Enabling Technologies For Future Bio-Pharma Research
Apr 11Calculating The Fair Value Of Bruker Corporation (NASDAQ:BRKR)
Jan 22There's Reason For Concern Over Bruker Corporation's (NASDAQ:BRKR) Price
Jan 08Should You Be Adding Bruker (NASDAQ:BRKR) To Your Watchlist Today?
Dec 26Is Bruker Corporation (NASDAQ:BRKR) Potentially Undervalued?
Nov 06Is Bruker (NASDAQ:BRKR) Using Too Much Debt?
Oct 23Here's Why Bruker (NASDAQ:BRKR) Has Caught The Eye Of Investors
Sep 25Does This Valuation Of Bruker Corporation (NASDAQ:BRKR) Imply Investors Are Overpaying?
Aug 09Is Now The Time To Look At Buying Bruker Corporation (NASDAQ:BRKR)?
Jul 27Bruker (NASDAQ:BRKR) Has A Pretty Healthy Balance Sheet
Jul 11Analyse de la rémunération des PDG
| Date | Rémunération totale | Salaire | Bénéfices de l'entreprise |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | US$305m |
| Jun 30 2024 | n/a | n/a | US$352m |
| Mar 31 2024 | n/a | n/a | US$402m |
| Dec 31 2023 | US$6m | US$926k | US$427m |
| Sep 30 2023 | n/a | n/a | US$319m |
| Jun 30 2023 | n/a | n/a | US$319m |
| Mar 31 2023 | n/a | n/a | US$312m |
| Dec 31 2022 | US$5m | US$873k | US$297m |
| Sep 30 2022 | n/a | n/a | US$275m |
| Jun 30 2022 | n/a | n/a | US$274m |
| Mar 31 2022 | n/a | n/a | US$282m |
| Dec 31 2021 | US$6m | US$812k | US$277m |
| Sep 30 2021 | n/a | n/a | US$270m |
| Jun 30 2021 | n/a | n/a | US$238m |
| Mar 31 2021 | n/a | n/a | US$204m |
| Dec 31 2020 | US$4m | US$689k | US$158m |
| Sep 30 2020 | n/a | n/a | US$158m |
| Jun 30 2020 | n/a | n/a | US$165m |
| Mar 31 2020 | n/a | n/a | US$177m |
| Dec 31 2019 | US$5m | US$753k | US$197m |
| Sep 30 2019 | n/a | n/a | US$207m |
| Jun 30 2019 | n/a | n/a | US$189m |
| Mar 31 2019 | n/a | n/a | US$184m |
| Dec 31 2018 | US$4m | US$731k | US$180m |
| Sep 30 2018 | n/a | n/a | US$98m |
| Jun 30 2018 | n/a | n/a | US$92m |
| Mar 31 2018 | n/a | n/a | US$84m |
| Dec 31 2017 | US$5m | US$704k | US$79m |
Rémunération vs marché: La rémunération totale de Frank ($USD 5.86M ) est dans la moyenne des entreprises de taille similaire sur le marché US ($USD 7.74M ).
Rémunération et revenus: La rémunération de Frank a été cohérente avec les performances de l'entreprise au cours de l'année écoulée.
PDG
Frank Laukien (64 yo)
33.8yrs
Titularisation
US$5,858,761
Compensation
Dr. Frank H. Laukien, Ph D., serves as the Chairman, Chief Executive Officer and President of Bruker Corporation at Bruker BioSpin GmbH since February 1991. Dr. Laukien serves as the Chairman, Chief Execut...
Équipe de direction
| Nom | Position | Titularisation | Compensation | Propriété |
|---|---|---|---|---|
| Chairman | 33.8yrs | US$5.86m | 26.62% $ 2.3b | |
| Executive VP & CFO | 6.7yrs | US$2.20m | 0.033% $ 2.8m | |
| Corporate Executive VP and President of Bruker Nano Group & Corporate | 9.3yrs | US$2.73m | 0.050% $ 4.4m | |
| President of Bruker CALID Group & Bruker Daltonics Division | 11.8yrs | US$1.47m | 0.081% $ 7.0m | |
| President of Bruker BioSpin Group | 6.5yrs | US$1.35m | 0.016% $ 1.4m | |
| Senior Director of Investor Relations & Corporate Development | no data | pas de données | pas de données | |
| General Counsel & Secretary | no data | pas de données | pas de données | |
| President and CEO of Bruker Energy & Supercon Technologies | 16.6yrs | US$967.91k | 0.0090% $ 776.9k |
10.6yrs
Durée moyenne de l'emploi
62yo
Âge moyen
Gestion expérimentée: L'équipe dirigeante de BRKR est chevronnée et expérimentée (10.6 années d'ancienneté moyenne).
Membres du conseil d'administration
| Nom | Position | Titularisation | Compensation | Propriété |
|---|---|---|---|---|
| Chairman | 33.8yrs | US$5.86m | 26.62% $ 2.3b | |
| Independent Director | 9.3yrs | US$241.01k | 0.014% $ 1.2m | |
| Independent Director | 9yrs | US$224.01k | 0.019% $ 1.6m | |
| Independent Director | 17.5yrs | US$227.32k | 0.047% $ 4.1m | |
| Independent Lead Director | 24.8yrs | US$231.01k | 0.022% $ 1.9m | |
| Independent Director | 7.5yrs | US$224.01k | 0.013% $ 1.1m | |
| Independent Director | 9.3yrs | US$219.01k | 0.014% $ 1.2m | |
| Independent Director | 4.2yrs | US$219.65k | 0.0050% $ 436.9k | |
| Independent Director | 8.5yrs | US$216.83k | 0.0076% $ 661.0k |
9.3yrs
Durée moyenne de l'emploi
66yo
Âge moyen
Conseil d'administration expérimenté: Les membres du conseil d'administration de BRKR sont considérés comme expérimentés (ancienneté moyenne 9.3 ans).